Cargando…

Serum Prolactin Levels in Patients with Major Depressive Disorder Receiving Selective Serotonin-Reuptake Inhibitor Monotherapy for 3 Months: A Prospective Study

OBJECTIVE: It is unclear whether selective serotonin-reuptake inhibitors (SSRIs) can significantly increase the prolactin level. The purpose of this study was to identify the relationship between the prolactin level and the administration of SSRIs such as escitalopram and sertraline. An additional p...

Descripción completa

Detalles Bibliográficos
Autor principal:	Park, Young-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neuropsychiatric Association 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440440/ https://www.ncbi.nlm.nih.gov/pubmed/28539956 http://dx.doi.org/10.4306/pi.2017.14.3.368

Ejemplares similares

Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer
por: Ashbury, Janet E., et al.
Publicado: (2012)

Serum Prolactin and Macroprolactin Levels among Outpatients with Major Depressive Disorder Following the Administration of Selective Serotonin-Reuptake Inhibitors: A Cross-Sectional Pilot Study
por: Kim, Sollip, et al.
Publicado: (2013)

Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression
por: James, Gregory M., et al.
Publicado: (2017)

Upper gastrointestinal bleeding in a patient with depression receiving selective serotonin reuptake inhibitor therapy
por: Kumar, Deepak, et al.
Publicado: (2009)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study
por: Margoob, Mushtaq A., et al.
Publicado: (2008)

Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
por: Dziurkowska, Ewelina, et al.
Publicado: (2013)

Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder
por: Keating, Charlotte, et al.
Publicado: (2013)

Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression
por: Hieronymus, F, et al.
Publicado: (2016)

Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis
por: Johnson, Chris F, et al.
Publicado: (2022)

RAVE DRUG (ECSTASY) AND SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTI-DEPRESSANTS
por: Singh, A.N., et al.
Publicado: (2000)

Rapid response to selective serotonin reuptake inhibitors in post-COVID depression
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick, Diego, et al.
Publicado: (2016)

Clinical pharmacology of serotonin selective reuptake inhibitors /
por: Preskorn, Sheldon
Publicado: (1996)

Selective serotonin reuptake inhibitors and Alzheimer’s disease
por: Mdawar, Bernadette, et al.
Publicado: (2019)

Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Qin, Sisi, et al.
Publicado: (2019)

Commentary: “Consistent Superiority of Selective Serotonin Reuptake Inhibitors Over Placebo in Reducing Depressed Mood in Patients with Major Depression”
por: Fried, Eiko I., et al.
Publicado: (2015)

The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring
por: Olivier, J. D. A., et al.
Publicado: (2013)

Depression and the Use of Selective Serotonin Reuptake Inhibitors in Patients with Acute Intracerebral Hemorrhage
por: Syed, Maryam J, et al.
Publicado: (2019)

Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
por: Gök, Soner, et al.
Publicado: (2023)

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics
por: Ji, Yuan, et al.
Publicado: (2012)

Effect of Selective Serotonin Reuptake Inhibitors and Immunomodulator on Cytokines Levels: An Alternative Therapy for Patients with Major Depressive Disorder
por: Hernandez, María Eugenia, et al.
Publicado: (2013)

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder
por: Martinez, James M, et al.
Publicado: (2015)

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Amare, Azmeraw T., et al.
Publicado: (2018)

Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
por: Nazarinasab, Masoumeh, et al.
Publicado: (2022)

Heart Rate Recovery and Selective Serotonin Reuptake Inhibitors
por: Cerit, Levent
Publicado: (2016)

Selective serotonin reuptake inhibitor-induced galactorrhea with hyperprolactinemia
por: Bhattacharjee, Subir, et al.
Publicado: (2021)

Confounding by Indication in Studies of Selective Serotonin Reuptake Inhibitors
por: Lee, Jimin, et al.
Publicado: (2022)

Estrogenic/antiestrogenic activity of selected selective serotonin reuptake inhibitors
por: POP, ANCA, et al.
Publicado: (2015)

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†
por: Montgomery, Stuart A, et al.
Publicado: (2014)

A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
por: Zhong, Zhuoyuan, et al.
Publicado: (2017)

Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk
por: Srivastava, Ankit, et al.
Publicado: (2019)

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010)

Long-Term Use of Selective Serotonin Reuptake Inhibitors and Risk of Glaucoma in Depression Patients
por: Chen, Hsin-Yi, et al.
Publicado: (2015)

Brain Imaging Study on the Pathogenesis of Depression & Therapeutic Effect of Selective Serotonin Reuptake Inhibitors
por: Meng, Qi, et al.
Publicado: (2020)

Apathy syndrome in a patient previously treated with selective serotonin reuptake inhibitors for depression
por: Kim, Hye-Geum, et al.
Publicado: (2019)

The complex clinical response to selective serotonin reuptake inhibitors in depression: a network perspective
por: Boschloo, Lynn, et al.
Publicado: (2023)

Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs)
por: Nikzad, Faezeh, et al.
Publicado: (2021)

Candidate genes for antidepressant response to selective serotonin reuptake inhibitors
por: Lotrich, Francis E, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_3421h8jgt7o7t2l4166bif34ak